

PhD in Intelligenza Artificiale in medicina e innovazione nella ricerca clinica e metodologica

Coordinatore: Prof. Domenico Russo

*Identifying of novel gene expression signatures in
Acute Myeloid Leukemia (AML) patients:
comparison of different methodological approaches*

Dottorandi XXXIX ciclo

Adriana Blanda

Supervisor: Prof. Russo Domenico




UNIVERSITÀ
DEGLI STUDI
DI BRESCIA



FONDAZIONE IRCCS
ISTITUTO NAZIONALE
DEI TUMORI ¹

OUTLINE:

- I. Background
- II. Aims
- III. Methods
- IV. Results
- V. Next Steps



I. Background

Acute myeloid leukaemia (AML) is a type of blood cancer. AML starts from the fast and uncontrolled growth of early myeloid blood cells in the bone marrow. The bone marrow is the soft inner part of the bones, where new blood cells are made.

AML is a biologically and clinically heterogeneous clonal disorder of hematopoietic progenitor cells, driven by a complex interplay of **cytogenetic** and molecular aberrations.

Risk stratification in AML is primarily based on cytogenetic abnormalities and recurrent gene mutations, as outlined by **ELN** and **WHO** classifications. These genetic lesions influence leukemogenesis, treatment response, and overall prognosis.

Emerging evidence suggests that the combinatorial effects of specific gene mutations—such as those in NPM1, FLT3, DNMT3A, and others—can modulate disease behavior and therapeutic sensitivity.

Integrative genomic profiling holds the potential to refine prognostic models and identify molecular signatures associated with improved survival outcomes, paving

I. Background

As of 2025, the estimated 5-year survival rate for AML is approximately **29.8% to 32%**



For individuals ***under 60 years*** of age, the 5-year survival rate ranges from **30% to 40%**

For patients ***over 60***, the 5-year survival rate decreases to **less than 20%**

In paediatric cases, particularly those ***under 15 years old***, survival rates can be significantly higher, reaching up to **67%**

II. Aims

1. To identify and validate one or more gene signatures related to outcome in terms of survival. (Survival Cox Regression)
2. To identify and validate one or more gene signatures **related to the cytogenetic risk**. (Logistic Regression)
3. To characterize and compare the above identify signatures especially in terms of involved biological pathways by gene ontology and enrichment analysis.

III. Methods

DISCOVERY - TRAINING

Gene Expression Omnibus (GEO) is a public repository maintained by the National Center for Biotechnology Information (NCBI), specifically designed to store and provide open access to gene expression, transcriptomic, and other genomic data.

Dataset: GSE6891*
#pts: 457[15-60y]
#genes: 20888
event: 290 dead
Median FU: 205 [IQR: 45-272]

*Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Löwenberg B, Delwel R, Valk PJ. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. *Haematologica*. 2009 Jan;94(1):131-4. doi: 10.3324/haematol.13299. Epub 2008 Oct 6. PMID: 18838472; PMCID: PMC2625407.

DISCOVERY DATASET


GSE6891

Clinic variables		N	%
Gender			
F		228	50%
M		229	50%
Age,median[Q1-Q3]		43[33-53]	
Score			
FABM0		16	4%
FABM1		94	21%
FABM2		104	23%
FABM3		24	5%
FABM4		79	17%
FABM4E		5	1%
FABM5		103	23%
FABM6		6	1%
FABMX		1	0%
FABUNK		8	2%
RAEB		4	1%
RAEB-T		13	3%
Risk			
good		97	21%
intermediate		259	57%
poor		91	20%
unknown		10	2%


Mutation			
npm1	neg	318	70%
	pos	139	30%
evi1	neg	426	93%
	pos	31	7%
n_ras	neg	411	90%
	pos	45	10%
1 NA			
Flt3_tkd	neg	407	89%
	pos	50	11%
Cebpa	neg	422	92%
	pos	31	7%
4 NA			
Flt3_itd	neg	333	73%
	pos	124	27%
K_ras	neg	453	99%
	pos	4	1%
Idh1	neg	420	92%
	pos	34	7%
3 NA			
Idh2	neg	417	91%
	pos	37	8%
3 NA			

III. Methods


GSE6891



Internal dataset




External dataset



III. Methods

207
candidates
genes



III. Methods

C-Index (Concordance Index) measures the discriminative ability of a survival model.

Integrated Brier Score (IBS) evaluates the overall predictive accuracy over time.

Evaluation metrics

$$\text{C-index} = \frac{\sum_{i,j} 1_{T_j < T_i} \cdot 1_{\eta_j > \eta_i} \cdot \delta_j}{\sum_{i,j} 1_{T_j < T_i} \cdot \delta_j}$$

η_i , the risk score of a unit i
 $1_{T_j < T_i} = 1$ if $T_j < T_i$ else 0
 $1_{\eta_j > \eta_i} = 1$ if $\eta_j > \eta_i$ else 0

$$\text{IBS}(t_{\max}) = \frac{1}{t_{\max}} \int_0^{t_{\max}} \text{BS}(t) dt$$

$$\text{BS}(t) = \frac{1}{N} \sum_{i=1}^N \left(\frac{\left(0 - \hat{S}(t, \vec{x}_i)\right)^2 \cdot 1_{T_i \leq t, \delta_i=1}}{\hat{G}(T_i^-)} + \frac{\left(1 - \hat{S}(t, \vec{x}_i)\right)^2 \cdot 1_{T_i > t}}{\hat{G}(t)} \right)$$

IV. Results

Bonferroni	LASSO	Elastic-net	Forward	Backward	SRF	BMA
CA13	CA13	CA13	CA13	BCHE	CA13	CA13
CDCP1	CDCP1	CDCP1	TEDC2_AS1	KRT8	CDCP1	TMEM79
	TEDC2_AS1		CDCP1	MADCAM1	TEDC2_AS1	ZGLP1
	TMEM79		PRRG1	PROCR		ZNF311
			ZGLP1	PTHLH		TEDC2_AS1
				EDC2_AS1		CDCP1
				CDCP1		PRRG1
				HEY2		
				TMEM79		

White-box: Supervised	
Bonferroni	adjustment for multiple comparisons
LASSO-COX	L1 regularitation
Elastic-net	L1 regularitation and alpha
BACKWARD selection	It starts with all variables and removes them one at a time
FORWARD selection	It starts with no variables and adds them one at a time
BMA	Bayesian Approach


IV. Results



White-box: Supervised – BMA (Bayesian Model Averaging)

Bayesian Approach

$$P(A|B) = \frac{P(B|A) P(A)}{P(B)}$$



BMA


- CA13
- TMEM79
- ZGLP1
- ZNF311
- TEDC2_AS1
- CDCP1
- PRRG1

IV. Results


Parameter Tuning

- Mtry
- Nodesize
- Ntree

● Black-box: Supervised – SRF:
Survival Random Forest





IV. Results



- **Activation function:** ReLu - sigmoid
- **Batch Normalization:** yes
- **Dropout:** 30%
- **Convergence Algorithm:** ADAM
- **Weight initialization:** He method
- **Loss function:** Accuracy




Black-box: Supervised – DeepSurv Cox Neural Network



IV. Results



XAI: Explainable Artificial Intelligence



In a SHAP summary plot, each point represents an individual instance's SHAP value for a specific feature.


The color of the point indicates the original value of that feature: **red** denotes high feature values **blue** signifies low feature values.

IV. Results

*Gene Ontology
analysis of genes
selected by the
Cox Neural
Network*

Biological Process (BP)
Molecular Function (MF)
Cellular Component (CC)

BIOLOGICAL PROCESS



IV. Results

*Gene Ontology
analysis of genes
selected by the
Cox Neural
Network*

Biological Process (BP)
Molecular Function (MF)
Cellular Component (CC)


MOLECULAR FUNCTION



IV. Results


*Gene Ontology
analysis of genes
selected by the
Cox Neural
Network*

Biological Process (BP)
Molecular Function (MF)
Cellular Component (CC)




IV. Results

t-SNE (t-Distributed Stochastic Neighbor Embedding) is a method based on variance for each feature




Unsupervised Learning: t-SNE




IV. Results

t-SNE (t-Distributed Stochastic Neighbor Embedding) is a powerful tool for visualizing high-dimensional data. It is widely used in data science and machine learning for its ability to reduce dimensions while preserving the local structure of the data.




Unsupervised Learning: t-SNE




IV. Results

Gene Ontology analysis of genes selected by the t-SNE


Biological Process



Molecular Function



Component Cellular



IV. Results

Bologna
Data
Policlinico
Sant'Orsola

External dataset

74 patients
36619 raw RNA-seq samples



RNA-seq data normalization performed with **edgeR**



74 patients
22681 raw RNA-seq samples

IV. Results

Bologna Dati
Policlinico
Sant’Orsola

Event: 40
Median fu: 17[6-29] months

27 relapse

External dataset


Clinic variables	N	%
Gender		
F	28	37.90%
M	46	62.10%
Age,median[Q1-Q3	65[23-92]	
Risk		
HIGH	22	
INTERMEDIATE	24	
LOW	23	

Mutation			
npm1			
	neg	38	58%
	pos	28	42%
8 NA			
evi1			
	neg	32	57%
	pos		
42 NA			
n_ras			
	neg	10	63%
	pos	6	38%
58 NA			
Flt3_tkd			
	neg	29	91%
	pos	3	9%
42 NA			
Cebpa			
	neg	30	40%
	pos	-	-
44 NA			
Flt3_itd			
	neg	26	81%
	pos	6	19%
42 NA			
K_ras			
	neg	14	88%
	pos	2	12%
58 NA			
Idh1			
	neg	28	93%
	pos	2	7%
44 NA			
Idh2			
	neg	28	93%
	pos	2	7%
44 NA			
TP53			
	neg	21	81%
	pos	23	19%
48 NA			

IV. Results

METRICS: C di HARRELL

Higher is better




C di Harrell											
SET	N	# eventi	Bonferroni	LASSO	Elastic-net	Forward	Backward	SRF	BMA	SHAP	t-SNE
Training 70%	321	203	0.61[0.57-0.65]	0.65[0.61-0.69]	0.61[0.57-0.65]	0.66[0.62-0.70]	0.67[0.63-0.71]	0.64[0.60-0.68]	0.66[0.62- 0.70]	0.65[0.61-0.69]	0.64[0.60-0.68]
Validation 30%	136	87	0.60[0.53-0.67]	0.60[0.53-0.67]	0.60[0.53-0.67]	0.63[0.56-0.69]	0.60[0.53-0.67]	0.60[0.53-0.66]	0.63[0.56-0.69]	0.62[0.56-0.68]	0.64[0.58-0.70]
Testing - Bologna	68	36	0.59[0.47-0.72]	0.61[0.49-0.73]	0.59[0.47-0.72]	0.60[0.49-0.71]	0.72[0.64-0.80]	0.60[0.50-0.71]	0.59[0.48-0.70]	0.63[0.54-0.73]	0.67[0.57-0.76]

IV. Results

METRICS: IBS

Lower is better




IBS

SET	N	# eventi	Bonferroni	LASSO	Elastic-net	Forward	Backward	SRF	BMA	SHAP	t-SNE
Training 70%	321	203	0.17[0.15-0.21]	0.16[0.14-0.17]	0.17[0.15-0.21]	0.15[0.14-0.17]	0.15[0.13-0.16]	0.16[0.15-0.18]	0.15[0.13-0.16]	0.16[0.14-0.17]	0.16[0.14-0.17]
Validation 30%	136	87	0.17[0.15-0.20]	0.17[0.14-0.20]	0.17[0.15-0.20]	0.16[0.14-0.19]	0.17[0.14-0.19]	0.17[0.14-0.20]	0.16[0.14-0.19]	0.16[0.14-0.19]	0.16[0.13-0.19]
Testing - Bologna	68	36	0.16[0.11-0.20]	0.17[0.11-0.21]	0.16[0.11-0.20]	0.16[0.11-0.20]	0.13[0.1-0.19]	0.16[0.11-0.20]	0.17[0.11-0.21]	0.15[0.10-0.19]	0.14[0.10-0.20]

NEXTS STEP

1. Validating the identified signature(s) on external datasets



2. Repeat all the previous analyses for the logistic outcome related to risk stratification